Wedbush lowered the firm’s price target on Xenon Pharmaceuticals (XENE) to $42 from $43 and keeps an Outperform rating on the shares. Most ...
This reduces the requirement for much heavier chemical fuel, thereby lowering launch cost, while increasing travel range. Whether through oxidation, coordination or ionization, xenon has revealed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results